Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

NCT02237690 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Doxorubicin hydrochloride liposome

Sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.